2026年5月11日 美国东部时间下午3:54 / 哥伦比亚广播公司新闻
华盛顿——美国最高法院周一延长了一项临时命令，目前将维持这款广泛使用的堕胎药米非司酮的邮寄渠道。
大法官塞缪尔·阿利托在一份简短的命令中表示，他上周签署的行政暂缓令将至少维持至周四下午5点。此举为最高法院留出了更多时间，以考虑是否要冻结一家上诉法院的裁决。该裁决恢复了美国食品药品监督管理局的一项规定，要求米非司酮必须当面配发。
该药物的两家制药企业——丹科实验室和GenBioPro公司本月早些时候曾请求最高法院搁置美国第五巡回上诉法院的这项裁决，并允许堕胎服务提供者在法律程序进行期间，通过线上开具处方并将药物邮寄给患者。阿利托负责处理来自第五巡回上诉法院的紧急上诉。
米非司酮需与另一种药物米索前列醇联合使用，以终止早期妊娠。支持堕胎权的研究组织古特马赫研究所的数据显示，2023年，药物流产占所有临床堕胎案例的65%。
但去年，路易斯安那州官员就美国食品药品监督管理局允许邮寄米非司酮的监管规定提起诉讼，这一诉讼有可能限制全美女性获取该药物的渠道，包括在堕胎合法的州。该州辩称，FDA的政策允许医疗服务提供者规避该州近乎全面的堕胎禁令。路易斯安那州官员表示，因此有“大量米非司酮”通过邮寄方式流入该州，每年导致“数千例”非法堕胎。
上个月，一家联邦地区法院暂停了路易斯安那州对FDA的诉讼，原因是该机构正在审查米非司酮的安全性。但路易斯安那州官员对这一裁决提起上诉，第五巡回上诉法院同意暂时叫停2023年的政策，该政策允许远程开具米非司酮处方并通过邮寄方式配送药物。
第五巡回上诉法院的全体一致合议庭裁决称：“FDA的行动所促成的每一例堕胎，都抵消了路易斯安那州对药物流产的禁令，破坏了其‘每一个未出生的孩子从受孕那一刻起就是人类，因此是法律上的人’的政策。”
https://www.cbsnews.com/video/abortions-increased-since-roe-v-wade-overturning-study/
Supreme Court continues to temporarily maintain mail access to abortion pill mifepristone
May 11, 2026 3:54 PM EDT / CBS News
Washington — The Supreme Court on Monday extended a temporary order maintaining mail access to the widely used abortion pill mifepristone for now.
Justice Samuel Alito said in a brief order that an administrative stay that he entered last week will remain in place until at least Thursday at 5 p.m. His move gives the Supreme Court additional time to consider whether to freeze an appellate court decision restoring a Food and Drug Administration rule that required mifepristone to be dispensed in person.
Two pharmaceutical companies that manufacture the drug, Danco Laboratories and GenBioPro, had asked the Supreme Court earlier this month to set aside that ruling from the U.S. Court of Appeals for the 5th Circuit and continue allowing abortion providers to prescribe the drug online and send it to patients while legal proceedings continue. Alito handles emergency appeals arising from the 5th Circuit.
Mifepristone is taken together with a second drug, misoprostol, to terminate an early pregnancy. Medication was used in 65% of all clinician-provided abortions in 2023, according to the Guttmacher Institute, a research organization that supports abortion rights.
But last year, Louisiana officials sued the FDA over its regulation allowing mifepristone to be mailed, which threatened to restrict access to the pill for women nationwide, including in states where abortion is legal. The state has argued that the FDA’s policy allows providers to circumvent its near-total ban on abortion. As a result, “streams of mifepristone” are sent into Louisiana by mail, leading to “thousands” of unlawful abortions each year, Louisiana officials said.
A federal district court had paused Louisiana’s case against the FDA last month while the agency reviews mifepristone’s safety. But Louisiana officials appealed that decision, and the 5th Circuit agreed to temporarily block the 2023 policy allowing mifepristone to be prescribed remotely and sent through the mail.
“Every abortion facilitated by FDA’s action cancels Louisiana’s ban on medical abortions and undermines its policy that ‘every unborn child is human being from the moment of conception and is, therefore, a legal person,’” the unanimous 5th Circuit panel found.
https://www.cbsnews.com/video/abortions-increased-since-roe-v-wade-overturning-study/
发表回复